UBS Group
EVGN icon

UBS Group’s Evogene EVGN Stock Holding History

UBS Group’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.89K Buy
6,352
+5,155
+431% +$4.87K ﹤0.01% 8871
2025
Q4 		$1.32K Sell
1,197
-4
-0.3% -$5 ﹤0.01% 9632
2025
Q3 		$1.37K Sell
1,201
-5,528
-82% -$7K ﹤0.01% 9363
2025
Q2 		$8.61K Sell
6,729
-12,016
-64% -$14.7K ﹤0.01% 8938
2025
Q1 		$23.4K Sell
18,745
-3,267
-15% -$4.93K ﹤0.01% 8120
2024
Q4 		$41.2K Buy
22,012
+13,411
+156% +$26.4K ﹤0.01% 7420
2024
Q3 		$26.4K Buy
8,601
+2,000
+30% +$8.63K ﹤0.01% 7191
2024
Q2 		$42.9K Buy
6,601
+351
+6% +$2.45K ﹤0.01% 6817
2024
Q1 		$46.9K Buy
6,250
+649
+12% +$5.41K ﹤0.01% 6537
2023
Q4 		$47K Buy
5,601
+2,000
+56% +$12.6K ﹤0.01% 6566
2023
Q3 		$21.1K Buy
3,601
+699
+24% +$6.12K ﹤0.01% 6774
2023
Q2 		$31.1K Buy
2,902
+801
+38% +$5.41K ﹤0.01% 6700
2023
Q1 		$13.2K Sell
2,101
-3
-0.1% -$22 ﹤0.01% 7407
2022
Q4 		$14.7K Buy
2,104
+350
+20% +$2.47K ﹤0.01% 8048
2022
Q3 		$15K Buy
1,754
+303
+21% +$2.92K ﹤0.01% 7790
2022
Q2 		$11K Sell
1,451
-2,126
-59% -$20.8K ﹤0.01% 7798
2022
Q1 		$47K Sell
3,577
-1,876
-34% -$25.3K ﹤0.01% 6559
2021
Q4 		$90K Buy
5,453
+4,005
+277% +$90.9K ﹤0.01% 6404
2021
Q3 		$38K Sell
1,448
-2,078
-59% -$60.6K ﹤0.01% 6551
2021
Q2 		$121K Buy
3,526
+759
+27% +$29.7K ﹤0.01% 5735
2021
Q1 		$139K Buy
2,767
+22
+0.8% +$1.36K ﹤0.01% 5713
2020
Q4 		$129K Sell
2,745
-10,222
-79% -$360K ﹤0.01% 5522
2020
Q3 		$514K Sell
12,967
-18,640
-59% -$333K ﹤0.01% 4171
2020
Q2 		$316K Sell
31,607
-104,119
-77% -$1.13M ﹤0.01% 4481
2020
Q1 		$1.6M Sell
135,726
-1,358
-1% -$18.7K ﹤0.01% 2958
2019
Q4 		$2.08M Sell
137,084
-4,149
-3% -$62K ﹤0.01% 3509
2019
Q3 		$2.23M Sell
141,233
-3,459
-2% -$54.4K ﹤0.01% 3186
2019
Q2 		$2.33M Buy
144,692
+3,863
+3% +$71.5K ﹤0.01% 3006
2019
Q1 		$2.58M Buy
140,829
+8,875
+7% +$188K ﹤0.01% 2770
2018
Q4 		$2.61M Buy
131,954
+1,519
+1% +$38.4K ﹤0.01% 2766
2018
Q3 		$4.06M Buy
130,435
+1,682
+1% +$48.6K ﹤0.01% 2547
2018
Q2 		$3.68M Buy
128,753
+1,174
+0.9% +$35.8K ﹤0.01% 2606
2018
Q1 		$4.05M Sell
127,579
-254
-0.2% -$9.46K ﹤0.01% 2506
2017
Q4 		$3.92M Buy
127,833
+5,068
+4% +$199K ﹤0.01% 2591
2017
Q3 		$5.45M Buy
122,765
+7,822
+7% +$373K ﹤0.01% 2125
2017
Q2 		$5.82M Buy
114,943
+9,689
+9% +$501K ﹤0.01% 2011
2017
Q1 		$5.63M Buy
105,254
+9,653
+10% +$503K ﹤0.01% 1991
2016
Q4 		$4.88M Buy
95,601
+13,368
+16% +$765K ﹤0.01% 2118
2016
Q3 		$5.25M Buy
82,233
+7,632
+10% +$502K ﹤0.01% 1978
2016
Q2 		$4.66M Buy
74,601
+5,643
+8% +$393K ﹤0.01% 2006
2016
Q1 		$4.49M Buy
68,958
+4,587
+7% +$315K ﹤0.01% 1959
2015
Q4 		$5.18M Buy
64,371
+34,697
+117% +$2.58M ﹤0.01% 1932
2015
Q3 		$2.45M Buy
29,674
+6,371
+27% +$555K ﹤0.01% 2552
2015
Q2 		$2.06M Buy
23,303
+980
+4% +$94.9K ﹤0.01% 2952
2015
Q1 		$1.97M Buy
22,323
+7,440
+50% +$693K ﹤0.01% 2940
2014
Q4 		$1.37M Buy
+14,883
New +$1.58M ﹤0.01% 3292

Other funds holding EVGN

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
DSC
Daytona Street Capital Saint Louis, Missouri $130M AUM
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
TCM
Tradewinds Capital Management Bellingham, Washington $504M AUM 40.92% 1-Year Est. Return

UBS Group's EVGN Position: Q1 2026 in Review

UBS Group increased its Evogene (EVGN) stake by 431% in Q1 2026, buying an estimated $4.87K and bringing the position to 6,352 shares worth $4.89K. The position accounts for ﹤0.01% of the portfolio, ranked #8871.

UBS Group first reported a position in EVGN in Q4 2014 and has held it in 46 quarters since. The position peaked at $5.82M in Q2 2017. 15 funds tracked by Wall St. Rank hold EVGN as of Q1 2026.

  • UBS Group held 6,352 shares of Evogene worth $4.89K as of Q1 2026.
  • UBS Group bought 5,155 Evogene shares in Q1 2026, an estimated $4.87K.
  • Evogene made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8871 holding.
  • UBS Group first reported a position in Evogene in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Evogene position peaked at $5.82M in Q2 2017.
  • 15 funds tracked by Wall St. Rank held Evogene as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.